Praca naukowa
Combined CONVentional with HYPOfractionated regimen (CONV-HYPO) alternative instead of conventionally fractionated radiotherapy to improve treatment outcomes
Maciejewski Bogusław, Kraszkiewicz Małgorzata, Wojcieszek Piotr [et al.], Nowotwory Journal of Oncology, 2025, vol. 75, no. 1, pp.35 – 41. DOI:10.5603/njo.102209
Miszczyk M, Kraszkiewicz M, Moll M, Kaminiów K, Sobel S, Dolla Ł, Wojcieszek P, Rajwa P, Yanagisawa T, Nowicka Z, Shariat SF, Goldner G, Miszczyk L, Majewski W. Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity. Cancers (Basel). 2023 Feb 13;15(4):1180. doi: 10.3390/cancers15041180. PMID: 36831523; PMCID: PMC9954604.
Miszczyk M, Napieralska A, Woźniak G, Kraszkiewicz M, Gola M, Kalemba M, Głowacki G, Tomasik B, Kocot-Kępska M, Miszczyk L. Conventionally fractionated radiotherapy versus CyberKnife hypofractionated radiotherapy for painful vertebral haemangiomas – A randomized clinical trial. Radiother Oncol. 2022 Nov; 176:46-52. doi: 10.1016/j.radonc.2022.09.008. Epub 2022 Sep 19. PMID: 36184997.
Miszczyk M, Rembak-Szynkiewicz J, Magrowski Ł, Stawiski K, Namysł-Kaletka A, Napieralska A, Kraszkiewicz M, Woźniak G, Stąpór-Fudzińska M, Głowacki G, Pradere B, Laukhtina E, Rajwa P, Majewski W. The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer. Cancers (Basel). 2022 Mar 23;14(7):1613. doi: 10.3390/cancers14071613. PMID: 35406385; PMCID: PMC8997034.
Miszczyk M, Szołtysik M, Hasterok M, Goldner G, Rajwa P, Namysł-Kaletka A, Napieralska A, Kraszkiewicz M, Stąpór-Fudzińska M, Tomasik B, Woźniak G, Głowacki G, Kaminiów K, Moll M, Magrowski Ł, Majewski W. Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk. Biomedicines. 2022 Sep 30;10(10):2446. doi: 10.3390/biomedicines10102446. PMID: 36289708; PMCID: PMC9598896.
Kraszkiewicz M, Napieralska A, Wydmański J, Suwiński R, Majewski W. Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer. Technology in Cancer Research & Treatment. January 2022. doi:10.1177/15330338221086085.
Miszczyk L, Namysł-Kaletka A, Napieralska A, Kraszkiewicz M, Miszczyk M, Woźniak G, Stąpór-Fudzińska M, Głowacki G, Tukiendorf A. Stereotactic Ablative Radiotherapy for Prostate Cancer—The Treatment Results of 500 Patients and Analysis of Failures. Technology in Cancer Research & Treatment. 2019 Aug 28; 18:1533033819870815.
Kraszkiewicz M, Wydmanski J. Brain metastases from stomach cancer – The role of different treatment modalities and efficacy of palliative radiotherapy. Rep Pract Oncol Radiother. 2014 Aug 28;20(1):32-7. doi: 10.1016/j.rpor.2014.08.003.
Kraszkiewicz M, Napieralska A, Miszczyk L, Majewski W. Does Carcinoembryonic Antigen Serum Concentration Decrease Predicts Overall Survival in Patients with Unresectable Rectal Cancer after Radical Radiotherapy or Radiochemotherapy? International Journal of Radiation Oncology, Biology, Physics. 2019 Sep 1;105(1): E167.
Kraszkiewicz M, Napieralska A, Wydmanski J, Maciejewski BA, Majewski W. Radical Therapeutic Strategies for Primary Unresectable Rectal Cancer: Radiochemotherapy, Conventional Radiation Therapy, and Hyperfractionated Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. 2018 Nov 1;102(3): e9-10.
Wydmanski J, Grabinska K, Polanowski P, Namysl-Kaletka A, Kawczynski R, Kraszkiewicz M, Majewski W. Radiotherapy and chemoradiotherapy as a novel option for the treatment of locally advanced inoperable gastric adenocarcinoma: A phase II study. Mol Clin Oncol. 2014 Nov ;2(6):1150-1154. doi: 10.3892/mco.2014.348.